VivoSeq
Oncology

B-Cell Non Hodgkin Lymphoma

9

Pipeline Programs↗

8

Active Trials↗

7

Companies Involved↗

B-cell Non Hodgkin Lymphoma is an early-stage landscape with 9 programs across 7 companies. The most active players are Suzhou Suncadia Biopharmaceuticals Co., Ltd., Taiho Oncology, Inc., Roche.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

19/100

Mech. Concentration

20/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

1 program

Phase 1Taiho Oncology, Inc. logo

Taiho Oncology, Inc.

1 program

Phase 1Roche logo

Roche

1 program

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 2AstraZeneca logo

AstraZeneca

3 programs

Phase 2S

Shanghai Helioson Pharmaceutical Co., Ltd.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

8programs
Small molecule450%
Monoclonal antibody225%
Cell therapy225%

Modality classified for 73% of 11 pipeline programs.

Analysis

Trial Status

8

clinical trials

Active, not recruiting3 · 38%
Recruiting3 · 38%
Not yet recruiting2 · 25%

Clinical Trials

Trial Activity

8 trials

A Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity of ARC-02 in Adult Participants With B-cell Non-Hodgkins Lymphoma (NHL)
Recruiting·Taiho Oncology, Inc. logoTaiho Oncology, Inc.·Phase 1·NCT07691606·140 enrolled
A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)
Recruiting·AstraZeneca logoAstraZeneca·Preclinical·NCT07123454·91 enrolled
A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)
Recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT06526793·270 enrolled
Phase II, Single Arm, Open Label, Study of the Combination of Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-Cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Active, not recruiting·NNorthwestern University·Phase 2·NCT06242834·32 enrolled
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT06464185·53 enrolled
Acalabrutinib in Combination With Anti-CD19 Chimeric Antigen Receptor T-Cells (CART) in B-Cell Lymphoma
Active, not recruiting·UUniversity of Washington·Preclinical·NCT04257578·23 enrolled
An Open-Label, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SHR-3079 Injection in Participants With B-Cell Non-Hodgkin Lymphoma
Not yet recruiting·Suzhou Suncadia Biopharmaceuticals Co., Ltd. logoSuzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 1·NCT07661537·90 enrolled
An Open-label, First-in-human Dose Escalation and Dose Expansion Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HP-002 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Not yet recruiting·SShanghai Helioson Pharmaceutical Co., Ltd.·Preclinical·NCT07658352·114 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)